Pharmacology/Pharmaceutical Industry
[Preprint] Effectiveness of a second COVID-19 vaccine booster on all-cause mortality in long-term care facility residents and in the oldest old: a nationwide, retrospective cohort study in Sweden.
18 May, 2022 | 11:05h | UTC
Commentary on Twitter
Confirmation of the 2nd booster protection from death in people age 80+ in Sweden, with a relative vaccine effectiveness 42% (compared w/ the 1st booster)https://t.co/Dq1x00J3Tr pic.twitter.com/fyXJPEcQzC
— Eric Topol (@EricTopol) May 17, 2022
M-A: Glucagon-like peptide-1 (GLP-1) receptor agonists and cardiovascular events in patients with type 2 diabetes mellitus.
18 May, 2022 | 10:53h | UTC
Commentary on Twitter
https://twitter.com/kamleshkhunti/status/1526474237481041921
Under a http://creativecommons.org/licenses/by/4.0/ license
Review: Role of direct oral anticoagulants for post-operative venous thromboembolism prophylaxis.
18 May, 2022 | 10:46h | UTC
Commentary on Twitter
Our work on this review summarises the pharmacological profile of DOACs and highlights the use of #DOACs in post-operative #VTE prophylaxis based on the available clinical trialhttps://t.co/7MRvWBfaEG @radcliffeCARDIO @mmamas1973 @AnastasiaSMihai @mirvatalasnag @KardiologieHH pic.twitter.com/MW6n2CWGe0
— Henry Han (@HanCardiomd) May 13, 2022
Under a CC-BY-NC 4.0 license
M-A: Tirzepatide cardiovascular event risk assessment.
18 May, 2022 | 10:34h | UTCTirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis – Nature Medicine
Commentary: Meta-analysis backs tirzepatide CV safety – medwireNews
Commentary on Twitter
https://twitter.com/NatureMedicine/status/1497179669476614150
Guideline Synopsis: Antithrombotic therapy for venous thromboembolism.
17 May, 2022 | 11:12h | UTCAntithrombotic Therapy for Venous Thromboembolism – JAMA (free for a limited period)
Original Guideline: Antithrombotic Therapy for VTE Disease
Second Update of the CHEST Guideline and Expert Panel Report
EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases.
17 May, 2022 | 10:54h | UTC
Commentary on Twitter
Our 2022 EULAR points to consider on Therapeutic drug monitoring of biologics just published in @ARD_BMJ
A real pleasure being part of this steering group & collaborative taskforce expertly led by @ProfJohnIsaacs
Clear points for practice& research👇https://t.co/YesEjajaIK pic.twitter.com/cQw8o1bjUw
— Meghna Jani (@MeghnaJani) May 15, 2022
RCT: Extended-course antibiotic prophylaxis in lower limb amputation.
17 May, 2022 | 10:50h | UTCExtended-course antibiotic prophylaxis in lower limb amputation: randomized clinical trial – British Journal of Surgery (link to abstract – $ for full-text)
Commentary on Twitter
In the May issue of BJS: Extended-course antibiotic prophylaxis in lower limb amputation: randomized clinical trial https://t.co/2H0TthufvZ @AmyLightnerMD @bplwijn @des_winter @ksoreide @MalinASund @evanscolorectal @nfmkok @robhinchliffe1 @young_bjs pic.twitter.com/taSa4Caibn
— BJS (@BJSurgery) April 30, 2022
Study Commentary | Antibiotics for pediatric pneumonia: might less be enough?
17 May, 2022 | 10:39h | UTCAntibiotics for Pediatric Pneumonia: Might Less Be Enough? – Annals of Emergency Medicine
Related:
Treatment of UTIs in Infants <2 Months: A Living Systematic Review – Hospital Pediatrics
Trial of a preferential Phosphodiesterase 4B Inhibitor for idiopathic pulmonary fibrosis.
16 May, 2022 | 02:32h | UTCTrial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary Fibrosis – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
https://twitter.com/NEJM/status/1525878684380430343
RCT: Comparison of 8 versus 15 days of antibiotic therapy for Pseudomonas aeruginosa ventilator-associated pneumonia in adults.
16 May, 2022 | 02:30h | UTCComparison of 8 versus 15 days of antibiotic therapy for Pseudomonas aeruginosa ventilator-associated pneumonia in adults: a randomized, controlled, open-label trial – Intensive Care Medicine (free article here)
Commentary on Twitter
🧫 8 vs 15 days ABT for Pseudomonas aeruginosa VAP in adults, iDIAPASON RCT: no differences in composite or separate outcomes (90-day mortality/VAP recurrence) between short & long duration treatment.
📢 @yourICM ground-breaking release #LIVES40 #FOAMcc
🖇 https://t.co/LfoUWxCkkl pic.twitter.com/XaWkQ5R6wT— Intensive Care Medicine (@yourICM) May 13, 2022
Test-negative, case-control study: Association of prior BNT162b2 COVID-19 vaccination with symptomatic SARS-CoV-2 infection in children and adolescents during Omicron predominance.
16 May, 2022 | 02:25h | UTCEditorial: Protecting Children Against Omicron – JAMA
Commentary on Twitter (thread – click for more)
This new JAMA study is worth discussing. It found that, this winter, vax effectiveness in 12-15 yos dropped to 0% after 3-5 months & vaccinated were MORE likely to test+ at month 7. May be confounded (see🧵)
But I don't see this as good reason for boostershttps://t.co/zpkIDdZhnn pic.twitter.com/bxAIDmiR8s— Tracy Høeg, MD, PhD (@TracyBethHoeg) May 14, 2022
RCT: Efficacy and safety of ultrahigh-dose Methylcobalamin in early-stage amyotrophic lateral sclerosis.
16 May, 2022 | 02:02h | UTCEfficacy and Safety of Ultrahigh-Dose Methylcobalamin in Early-Stage Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial – JAMA Neurology (link to abstract – $ for full-text)
Commentary on Twitter
A phase 3 clinical trial found ultra-high dose methylcobalamin slowed functional decline in patients with early-stage amyotrophic lateral sclerosis. https://t.co/r5KP38JkUc
— JAMA Neurology (@JAMANeuro) May 9, 2022
RCT: Dorzagliatin add-on therapy to metformin in patients with type 2 diabetes.
16 May, 2022 | 01:51h | UTCCommentary: DAWN: Support for dorzagliatin–metformin combination therapy in type 2 diabetes – medwireNews
Commentary on Twitter
The DAWN study is a #phase3 clinical trial that demonstrates effective #glycemic control of #dorzagliatin as an add-on therapy to #metfomin in patients with type 2 #diabetes. #T2D #NMEDClinicalhttps://t.co/9bHWQNvNTJ
— Nature Medicine (@NatureMedicine) May 12, 2022
Oral pre-exposure prophylaxis (PrEP) to prevent HIV: a systematic review and meta-analysis of clinical effectiveness, safety, adherence and risk compensation in all populations.
16 May, 2022 | 01:41h | UTC
IDSA updates guidelines on the treatment and management of patients with COVID-19.
13 May, 2022 | 11:35h | UTC
Pharmacist-led review tied to better antimicrobial prescribing at discharge.
13 May, 2022 | 10:59h | UTCCommentary: Pharmacist-led review tied to better antimicrobial prescribing at discharge – CIDRAP
Original Study: Pharmacist-Driven Transitions of Care Practice Model for Prescribing Oral Antimicrobials at Hospital Discharge – JAMA Network Open
RCT: Evaluation of mRNA-1273 Covid-19 vaccine in children 6 to 11 years of age.
12 May, 2022 | 10:22h | UTC
Commentary on Twitter
Two 50-μg doses of mRNA-1273 vaccine were found to be safe and effective in inducing immune responses and preventing Covid-19 in children 6 to 11 years of age. https://t.co/A5SBK4zK6E pic.twitter.com/7x4JgOwK57
— NEJM (@NEJM) May 11, 2022
Systematic Review: Prevalence of opioid use disorder among patients with cancer-related pain.
11 May, 2022 | 10:46h | UTC
M-A: Interventions to improve immunization coverage among children and adolescents.
11 May, 2022 | 10:45h | UTC
ECRI and ISMP Public Statement | Medication errors are complex; criminal charges will not improve care.
10 May, 2022 | 11:29h | UTCSee also:
The simple thing hospitals can do to prevent dangerous drug mistakes – CNN
Review: First-generation oral antivirals against SARS-CoV-2.
10 May, 2022 | 11:08h | UTCFirst-generation Oral Antivirals Against SARS-CoV-2 – Clinical Microbiology and Infection
Review: Assessment and management of cognitive function in patients with prostate cancer treated with second-generation androgen receptor pathway inhibitors.
10 May, 2022 | 10:32h | UTC
Studies show promise for 2 new COVID vaccine platforms.
9 May, 2022 | 02:12h | UTCCommentary: Studies show promise for 2 new COVID vaccine platforms – CIDRAP
Editorial: Does the World Still Need New Covid-19 Vaccines?
Commentaries on Twitter
Efficacy of a plant-based vaccine with adjuvant was 69.5% against symptomatic #COVID19 and 78.8% against moderate-to-severe disease. https://t.co/WH54QWCBdg pic.twitter.com/BiEYpJUD7D
— NEJM (@NEJM) May 4, 2022
ZF2001 vaccine has 87% efficacy against critical or severe #COVID19 for at least 6 months after full vaccination and was safe in large cohort of adults. #IDTwitter https://t.co/wsG0AXqI4Y pic.twitter.com/45fqwVrz9a
— NEJM (@NEJM) May 4, 2022
Systematic Review: Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis.
6 May, 2022 | 10:47h | UTCSummary: Cannabis and cannabinoids for people with multiple sclerosis – Cochrane Library
Commentary on Twitter
💚A UK survey found that 1 in 5 people with #MS reported they used #Cannabis to manage symptoms.
🤔 Does it work? Are there harms?
📚 Cochrane systematic review looks at 25 RCTs ➡️ https://t.co/HCt6Cx3suo#MedicalMarijuana #MultipleSclerosis pic.twitter.com/wjDTXXEciM— The Cochrane Library (@CochraneLibrary) May 5, 2022
Systematic Review: Clinical practice guideline recommendations on tapering and discontinuing antidepressants for depression.
6 May, 2022 | 10:37h | UTCRelated:
Discontinuing antidepressants: Pearls and pitfalls.
A method for tapering antipsychotic treatment that may minimize the risk of relapse
Systematic Review: Managing Antidepressant Discontinuation
Randomized controlled trial: preventive cognitive therapy for prevention of depressive recurrence